We have located links that may give you full text access.
Correlations between antinucleosome antibodies and anti-double-stranded DNA antibodies, C3, C4, and clinical activity in lupus patients.
Clinical and Experimental Rheumatology 2006 January
OBJECTIVE: To examine the correlations between antinucleosome antibodies and anti-double-stranded (ds) DNA antibodies, complement (C) 3 and 4 levels, and clinical activities in SLE patients.
METHODS: Antinucleosome antibodies and anti-dsDNA antibodies were detected by enzyme-linked immunosorbent assays (ELISA). The levels of C3 and C4 were measured by nephelometry. Clinical activities were determined by SLE Disease Activity Index (SLEDAI).
RESULTS: Of 65 SLE patients, the prevalence of antinucleosome antibodies were higher than anti-ds DNA antibodies (52.3 vs 36.9%, respectively, p < 0.05). Similar results were obtained in 45 active SLE patients, 64.4% for antinucleosome antibodies and 46.7% for anti-ds DNA antibodies. Of 34 patients lacking anti-ds DNA antibodies, 16 (47.1%) were shown antinucleosome antibodies. Activity of antinucleosome antibodies was significantly correlated with the SLEDAI scores and inversedly correlated with the C3 levels but not with the C4 levels.
CONCLUSION: Antinucleosome antibodies could be one of the earliest and most sensitive markers in diagnosis of SLE, particularly in anti-dsDNA antibodies-negative patients. More importantly, antinucleosome antibodies is correlated with clinical activities and C3 levels.
METHODS: Antinucleosome antibodies and anti-dsDNA antibodies were detected by enzyme-linked immunosorbent assays (ELISA). The levels of C3 and C4 were measured by nephelometry. Clinical activities were determined by SLE Disease Activity Index (SLEDAI).
RESULTS: Of 65 SLE patients, the prevalence of antinucleosome antibodies were higher than anti-ds DNA antibodies (52.3 vs 36.9%, respectively, p < 0.05). Similar results were obtained in 45 active SLE patients, 64.4% for antinucleosome antibodies and 46.7% for anti-ds DNA antibodies. Of 34 patients lacking anti-ds DNA antibodies, 16 (47.1%) were shown antinucleosome antibodies. Activity of antinucleosome antibodies was significantly correlated with the SLEDAI scores and inversedly correlated with the C3 levels but not with the C4 levels.
CONCLUSION: Antinucleosome antibodies could be one of the earliest and most sensitive markers in diagnosis of SLE, particularly in anti-dsDNA antibodies-negative patients. More importantly, antinucleosome antibodies is correlated with clinical activities and C3 levels.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app